These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33140850)

  • 21. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential therapeutic applications of muscle-derived mesenchymal stem and progenitor cells.
    Jackson WM; Nesti LJ; Tuan RS
    Expert Opin Biol Ther; 2010 Apr; 10(4):505-17. PubMed ID: 20218920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesenchymal stromal cells retrovirally transduced with prodrug-converting genes are suitable vehicles for cancer gene therapy.
    Ďuriniková E; Kučerová L; Matúšková M
    Acta Virol; 2014; 58(1):1-13. PubMed ID: 24717023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stem Cell Therapy and Cats: What Do We Know at This Time.
    Webb TL
    Vet Clin North Am Small Anim Pract; 2020 Sep; 50(5):955-971. PubMed ID: 32665136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine.
    Goula A; Gkioka V; Michalopoulos E; Katsimpoulas M; Noutsias M; Sarri EF; Stavropoulos C; Kostakis A
    J Clin Med Res; 2020 Dec; 12(12):780-786. PubMed ID: 33447311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
    Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
    Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulatory Oversight of Cell and Gene Therapy Products in Malaysia.
    Loh EYX; Ab Ghani A; Ahmad R
    Adv Exp Med Biol; 2023; 1430():181-195. PubMed ID: 37526848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
    Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapeutic potential of human mesenchymal stromal cells secreted components: a problem with standartization].
    Sagaradze GD; Grigorieva OA; Efimenko AY; Chaplenko AA; Suslina SN; Sysoeva VY; Kalinina NI; Akopyan ZhA; Tkachuk VA
    Biomed Khim; 2015; 61(6):750-9. PubMed ID: 26716748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments.
    Azizi AA; Pillai M; Thistlethwaite FC
    Curr Opin Oncol; 2019 Sep; 31(5):430-438. PubMed ID: 31335828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Innovative, Comprehensive Mapping and Multiscale Analysis of Registered Trials for Stem Cell-Based Regenerative Medicine.
    Monsarrat P; Vergnes JN; Planat-Bénard V; Ravaud P; Kémoun P; Sensebé L; Casteilla L
    Stem Cells Transl Med; 2016 Jun; 5(6):826-35. PubMed ID: 27075765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges.
    Peltzer J; Aletti M; Frescaline N; Busson E; Lataillade JJ; Martinaud C
    Front Immunol; 2018; 9():2013. PubMed ID: 30271402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Translation of Mesenchymal Stromal Cell Therapies in Nephrology.
    Perico N; Casiraghi F; Remuzzi G
    J Am Soc Nephrol; 2018 Feb; 29(2):362-375. PubMed ID: 29191959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
    Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
    BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products).
    Cavero I; Seimetz D; Koziel D; Zimmermann WH; Holzgrefe HH
    Expert Opin Drug Saf; 2020 May; 19(5):553-558. PubMed ID: 32163309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concise Review: Cellular Therapies: The Potential to Regenerate and Restore Tolerance in Immune-Mediated Intestinal Diseases.
    Ciccocioppo R; Cangemi GC; Kruzliak P; Corazza GR
    Stem Cells; 2016 Jun; 34(6):1474-86. PubMed ID: 27016400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesenchymal Stem/Progenitor Cells Derived from Articular Cartilage, Synovial Membrane and Synovial Fluid for Cartilage Regeneration: Current Status and Future Perspectives.
    Huang YZ; Xie HQ; Silini A; Parolini O; Zhang Y; Deng L; Huang YC
    Stem Cell Rev Rep; 2017 Oct; 13(5):575-586. PubMed ID: 28721683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesenchymal Stromal Cells and Natural Killer Cells: A Complex Story of Love and Hate.
    Najar M; Fayyad-Kazan M; Merimi M; Burny A; Bron D; Fayyad-Kazan H; Meuleman N; Lagneaux L
    Curr Stem Cell Res Ther; 2019; 14(1):14-21. PubMed ID: 30207245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric Antigen Receptor beyond CAR-T Cells.
    Qin VM; D'Souza C; Neeson PJ; Zhu JJ
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33499101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.